カテゴリ： Transparency Market Research, 世界, 医療/バイオ

T細胞療法の世界市場（2023～2033）：疾患別、治療種類別、モダリティ別、地域別

■ 英語タイトル：Global T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumours and Other Indications), by Therapy Type (CAR T-cell Therapy, TCR-based and TIL-based), by Modality (Research and Commercialized) and Region - 2023 to 2033

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23AP140）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23AP140
■ 発行日：2023年1月19日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：250
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[T細胞療法の世界市場（2023～2033）：疾患別、治療種類別、モダリティ別、地域別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の本調査レポートでは、T細胞療法の世界市場について総合的に分析し、今後の市場動向を予測しています。本書は、エグゼクティブサマリー、市場概要、市場背景、市場動向、疾患別（血液悪性腫瘍、固形腫瘍、その他）分析、治療種類別（CAR T細胞療法、TCRベース、TILベース）分析、モダリティ別（調査、商業化）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、市場構造分析、競争分析などの項目が整理されています。また、本書内には、Novartis AG、Merck KGaA、Gilead Sciences Inc.、TCR2 Therapeutics Inc、Bluebird Bio Inc.、Sorrento Therapeutics、Fate Therapeutics、Pfizer Inc.、Amgen、Celgene Corporationなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場概要
・市場背景
・市場動向
・世界のT細胞療法市場規模：疾患別
- 血液悪性腫瘍における市場規模
- 固形腫瘍における市場規模
- その他疾患における市場規模
・世界のT細胞療法市場規模：治療種類別
- CAR T細胞療法の市場規模
- TCRベース治療の市場規模
- TILベース治療の市場規模
・世界のT細胞療法市場規模：モダリティ別
- 調査における市場規模
- 商業化における市場規模
・世界のT細胞療法市場規模：地域別
- 北米のT細胞療法市場規模
- 中南米のT細胞療法市場規模
- ヨーロッパのT細胞療法市場規模
- アジア太平洋のT細胞療法市場規模
- 中東・アフリカのT細胞療法市場規模
・市場構造分析
・競争分析

T-cell Therapy Market – Scope of Report
TMR’s report on the global T-cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2033. The report provides revenue of the global T-cell therapy market for the period 2017–2031, considering 2023 as the base year and 2033 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global T-cell therapy market from 2023 to 2033.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the T-cell therapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global T-cell therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global T-cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global T-cell therapy market.

The report delves into the competitive landscape of the global T-cell therapy market. Key players operating in the global T-cell therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global T-cell therapy market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market T-cell therapy.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. Value Chain Analysis
        3.5.1. Profit Margin Analysis
        3.5.2. Service Providers
    3.6. PESTLE and Porter’s Analysis
    3.7. Regulatory Landscape
        3.7.1. By Key Regions
        3.7.2. By Key Countries
    3.8. Regional Parent Market Outlook
4. Global T-cell Therapy Market Analysis 2018-2022 and Forecast, 2023-2033
    4.1. Historical Market Size Value (US$ Bn) Analysis, 2018-2022
    4.2. Current and Future Market Size Value (US$ Bn) Projections, 2023-2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Indication
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Bn) Analysis By Indication , 2018-2022
    5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication , 2023-2033
        5.3.1. Hematologic Malignancies
            5.3.1.1. Lymphoma
            5.3.1.2. Leukemia
            5.3.1.3. Myeloma
        5.3.2. Solid Tumors
            5.3.2.1. Melanoma
            5.3.2.2. Brain & Central Nervous System
            5.3.2.3. Liver Cancer
            5.3.2.4. Other Solid Tumors
        5.3.3. Other Indications
    5.4. Y-o-Y Growth Trend Analysis By Indication , 2018-2022
    5.5. Absolute $ Opportunity Analysis By Indication , 2023-2033
6. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Therapy Type
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Bn) Analysis By Therapy Type, 2018-2022
    6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Therapy Type, 2023-2033
        6.3.1. CAR T-cell Therapy
        6.3.2. T Cell Receptor (TCR)-based
        6.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
    6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018-2022
    6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023-2033
7. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Modality
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Bn) Analysis By Modality , 2018-2022
    7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Modality , 2023-2033
        7.3.1. Research
        7.3.2. Commercialized
    7.4. Y-o-Y Growth Trend Analysis By Modality , 2018-2022
    7.5. Absolute $ Opportunity Analysis By Modality , 2023-2033
8. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2018-2022
    8.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2023-2033
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Europe
        8.3.4. Asia Pacific
        8.3.5. MEA
    8.4. Market Attractiveness Analysis By Region
9. North America T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
    9.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
    9.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
        9.2.1. By Country
            9.2.1.1. U.S.
            9.2.1.2. Canada
        9.2.2. By Indication
        9.2.3. By Therapy Type
        9.2.4. By Modality
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Indication
        9.3.3. By Therapy Type
        9.3.4. By Modality
    9.4. Key Takeaways
10. Latin America T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
    10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
    10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Indication
        10.2.3. By Therapy Type
        10.2.4. By Modality
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Indication
        10.3.3. By Therapy Type
        10.3.4. By Modality
    10.4. Key Takeaways
11. Europe T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
    11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
    11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. Italy
            11.2.1.3. France
            11.2.1.4. U.K.
            11.2.1.5. Spain
            11.2.1.6. Russia
            11.2.1.7. Rest of Europe
        11.2.2. By Indication
        11.2.3. By Therapy Type
        11.2.4. By Modality
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Indication
        11.3.3. By Therapy Type
        11.3.4. By Modality
    11.4. Key Takeaways
12. Asia Pacific T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
    12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
    12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
        12.2.1. By Country
            12.2.1.1. China
            12.2.1.2. Japan
            12.2.1.3. India
            12.2.1.4. South Korea
            12.2.1.5. Australia
            12.2.1.6. Rest of APAC
        12.2.2. By Indication
        12.2.3. By Therapy Type
        12.2.4. By Modality
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Indication
        12.3.3. By Therapy Type
        12.3.4. By Modality
    12.4. Key Takeaways
13. MEA T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
    13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
    13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033
        13.2.1. By Country
            13.2.1.1. South Africa
            13.2.1.2. Saudi Arabia
            13.2.1.3. UAE
            13.2.1.4. Israel
            13.2.1.5. Rest of MEA
        13.2.2. By Indication
        13.2.3. By Therapy Type
        13.2.4. By Modality
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Indication
        13.3.3. By Therapy Type
        13.3.4. By Modality
    13.4. Key Takeaways
14. Key Countries T-cell Therapy Market Analysis
    14.1. U.S.
        14.1.1. Pricing Analysis
        14.1.2. Market Share Analysis, 2022
            14.1.2.1. By Indication
            14.1.2.2. By Therapy Type
            14.1.2.3. By Modality
    14.2. Canada
        14.2.1. Pricing Analysis
        14.2.2. Market Share Analysis, 2022
            14.2.2.1. By Indication
            14.2.2.2. By Therapy Type
            14.2.2.3. By Modality
    14.3. Brazil
        14.3.1. Pricing Analysis
        14.3.2. Market Share Analysis, 2022
            14.3.2.1. By Indication
            14.3.2.2. By Therapy Type
            14.3.2.3. By Modality
    14.4. Mexico
        14.4.1. Pricing Analysis
        14.4.2. Market Share Analysis, 2022
            14.4.2.1. By Indication
            14.4.2.2. By Therapy Type
            14.4.2.3. By Modality
    14.5. Germany
        14.5.1. Pricing Analysis
        14.5.2. Market Share Analysis, 2022
            14.5.2.1. By Indication
            14.5.2.2. By Therapy Type
            14.5.2.3. By Modality
    14.6. Italy
        14.6.1. Pricing Analysis
        14.6.2. Market Share Analysis, 2022
            14.6.2.1. By Indication
            14.6.2.2. By Therapy Type
            14.6.2.3. By Modality
    14.7. France
        14.7.1. Pricing Analysis
        14.7.2. Market Share Analysis, 2022
            14.7.2.1. By Indication
            14.7.2.2. By Therapy Type
            14.7.2.3. By Modality
    14.8. U.K.
        14.8.1. Pricing Analysis
        14.8.2. Market Share Analysis, 2022
            14.8.2.1. By Indication
            14.8.2.2. By Therapy Type
            14.8.2.3. By Modality
    14.9. Spain
        14.9.1. Pricing Analysis
        14.9.2. Market Share Analysis, 2022
            14.9.2.1. By Indication
            14.9.2.2. By Therapy Type
            14.9.2.3. By Modality
    14.10. Russia
        14.10.1. Pricing Analysis
        14.10.2. Market Share Analysis, 2022
            14.10.2.1. By Indication
            14.10.2.2. By Therapy Type
            14.10.2.3. By Modality
    14.11. China
        14.11.1. Pricing Analysis
        14.11.2. Market Share Analysis, 2022
            14.11.2.1. By Indication
            14.11.2.2. By Therapy Type
            14.11.2.3. By Modality
    14.12. Japan
        14.12.1. Pricing Analysis
        14.12.2. Market Share Analysis, 2022
            14.12.2.1. By Indication
            14.12.2.2. By Therapy Type
            14.12.2.3. By Modality
    14.13. India
        14.13.1. Pricing Analysis
        14.13.2. Market Share Analysis, 2022
            14.13.2.1. By Indication
            14.13.2.2. By Therapy Type
            14.13.2.3. By Modality
    14.14. South Korea
        14.14.1. Pricing Analysis
        14.14.2. Market Share Analysis, 2022
            14.14.2.1. By Indication
            14.14.2.2. By Therapy Type
            14.14.2.3. By Modality
    14.15. Australia
        14.15.1. Pricing Analysis
        14.15.2. Market Share Analysis, 2022
            14.15.2.1. By Indication
            14.15.2.2. By Therapy Type
            14.15.2.3. By Modality
    14.16. South Africa
        14.16.1. Pricing Analysis
        14.16.2. Market Share Analysis, 2022
            14.16.2.1. By Indication
            14.16.2.2. By Therapy Type
            14.16.2.3. By Modality
    14.17. Saudi Arabia
        14.17.1. Pricing Analysis
        14.17.2. Market Share Analysis, 2022
            14.17.2.1. By Indication
            14.17.2.2. By Therapy Type
            14.17.2.3. By Modality
    14.18. UAE
        14.18.1. Pricing Analysis
        14.18.2. Market Share Analysis, 2022
            14.18.2.1. By Indication
            14.18.2.2. By Therapy Type
            14.18.2.3. By Modality
    14.19. Israel
        14.19.1. Pricing Analysis
        14.19.2. Market Share Analysis, 2022
            14.19.2.1. By Indication
            14.19.2.2. By Therapy Type
            14.19.2.3. By Modality
15. Market Structure Analysis
    15.1. Competition Dashboard
    15.2. Competition Benchmarking
    15.3. Market Share Analysis of Top Players
        15.3.1. By Regional
        15.3.2. By Indication
        15.3.3. By Therapy Type
        15.3.4. By Modality
16. Competition Analysis
    16.1. Competition Deep Dive
        16.1.1. Novartis AG
            16.1.1.1. Overview
            16.1.1.2. Product Portfolio
            16.1.1.3. Profitability by Market Segments
            16.1.1.4. Sales Footprint
            16.1.1.5. Strategy Overview
                16.1.1.5.1. Marketing Strategy
                16.1.1.5.2. Product Strategy
                16.1.1.5.3. Channel Strategy
        16.1.2. Merck KGaA
            16.1.2.1. Overview
            16.1.2.2. Product Portfolio
            16.1.2.3. Profitability by Market Segments
            16.1.2.4. Sales Footprint
            16.1.2.5. Strategy Overview
                16.1.2.5.1. Marketing Strategy
                16.1.2.5.2. Product Strategy
                16.1.2.5.3. Channel Strategy
        16.1.3. Gilead Sciences Inc.
            16.1.3.1. Overview
            16.1.3.2. Product Portfolio
            16.1.3.3. Profitability by Market Segments
            16.1.3.4. Sales Footprint
            16.1.3.5. Strategy Overview
                16.1.3.5.1. Marketing Strategy
                16.1.3.5.2. Product Strategy
                16.1.3.5.3. Channel Strategy
        16.1.4. TCR2 Therapeutics Inc
            16.1.4.1. Overview
            16.1.4.2. Product Portfolio
            16.1.4.3. Profitability by Market Segments
            16.1.4.4. Sales Footprint
            16.1.4.5. Strategy Overview
                16.1.4.5.1. Marketing Strategy
                16.1.4.5.2. Product Strategy
                16.1.4.5.3. Channel Strategy
        16.1.5. Bluebird Bio Inc
            16.1.5.1. Overview
            16.1.5.2. Product Portfolio
            16.1.5.3. Profitability by Market Segments
            16.1.5.4. Sales Footprint
            16.1.5.5. Strategy Overview
                16.1.5.5.1. Marketing Strategy
                16.1.5.5.2. Product Strategy
                16.1.5.5.3. Channel Strategy
        16.1.6. Sorrento Therapeutics
            16.1.6.1. Overview
            16.1.6.2. Product Portfolio
            16.1.6.3. Profitability by Market Segments
            16.1.6.4. Sales Footprint
            16.1.6.5. Strategy Overview
                16.1.6.5.1. Marketing Strategy
                16.1.6.5.2. Product Strategy
                16.1.6.5.3. Channel Strategy
        16.1.7. Fate Therapeutics
            16.1.7.1. Overview
            16.1.7.2. Product Portfolio
            16.1.7.3. Profitability by Market Segments
            16.1.7.4. Sales Footprint
            16.1.7.5. Strategy Overview
                16.1.7.5.1. Marketing Strategy
                16.1.7.5.2. Product Strategy
                16.1.7.5.3. Channel Strategy
        16.1.8. Pfizer Inc
            16.1.8.1. Overview
            16.1.8.2. Product Portfolio
            16.1.8.3. Profitability by Market Segments
            16.1.8.4. Sales Footprint
            16.1.8.5. Strategy Overview
                16.1.8.5.1. Marketing Strategy
                16.1.8.5.2. Product Strategy
                16.1.8.5.3. Channel Strategy
        16.1.9. Amgen
            16.1.9.1. Overview
            16.1.9.2. Product Portfolio
            16.1.9.3. Profitability by Market Segments
            16.1.9.4. Sales Footprint
            16.1.9.5. Strategy Overview
                16.1.9.5.1. Marketing Strategy
                16.1.9.5.2. Product Strategy
                16.1.9.5.3. Channel Strategy
        16.1.10. Celgene Corporation
            16.1.10.1. Overview
            16.1.10.2. Product Portfolio
            16.1.10.3. Profitability by Market Segments
            16.1.10.4. Sales Footprint
            16.1.10.5. Strategy Overview
                16.1.10.5.1. Marketing Strategy
                16.1.10.5.2. Product Strategy
                16.1.10.5.3. Channel Strategy
17. Assumptions & Acronyms Used
18. Research Methodology

List of Tables

Table 1: Global T-cell Therapy Market Value (US$ Bn) Forecast by Region, 2018-2033

Table 2: Global T-cell Therapy Market Value (US$ Bn) Forecast by Indication , 2018-2033

Table 3: Global T-cell Therapy Market Value (US$ Bn) Forecast by Therapy Type, 2018-2033

Table 4: Global T-cell Therapy Market Value (US$ Bn) Forecast by Modality , 2018-2033

Table 5: North America T-cell Therapy Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 6: North America T-cell Therapy Market Value (US$ Bn) Forecast by Indication , 2018-2033

Table 7: North America T-cell Therapy Market Value (US$ Bn) Forecast by Therapy Type, 2018-2033

Table 8: North America T-cell Therapy Market Value (US$ Bn) Forecast by Modality , 2018-2033

Table 9: Latin America T-cell Therapy Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 10: Latin America T-cell Therapy Market Value (US$ Bn) Forecast by Indication , 2018-2033

Table 11: Latin America T-cell Therapy Market Value (US$ Bn) Forecast by Therapy Type, 2018-2033

Table 12: Latin America T-cell Therapy Market Value (US$ Bn) Forecast by Modality , 2018-2033

Table 13: Europe T-cell Therapy Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 14: Europe T-cell Therapy Market Value (US$ Bn) Forecast by Indication , 2018-2033

Table 15: Europe T-cell Therapy Market Value (US$ Bn) Forecast by Therapy Type, 2018-2033

Table 16: Europe T-cell Therapy Market Value (US$ Bn) Forecast by Modality , 2018-2033

Table 17: Asia Pacific T-cell Therapy Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 18: Asia Pacific T-cell Therapy Market Value (US$ Bn) Forecast by Indication , 2018-2033

Table 19: Asia Pacific T-cell Therapy Market Value (US$ Bn) Forecast by Therapy Type, 2018-2033

Table 20: Asia Pacific T-cell Therapy Market Value (US$ Bn) Forecast by Modality , 2018-2033

Table 21: MEA T-cell Therapy Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 22: MEA T-cell Therapy Market Value (US$ Bn) Forecast by Indication , 2018-2033

Table 23: MEA T-cell Therapy Market Value (US$ Bn) Forecast by Therapy Type, 2018-2033

Table 24: MEA T-cell Therapy Market Value (US$ Bn) Forecast by Modality , 2018-2033

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 遺伝子合成の世界市場（2023～2033）：手法別、サービス種類別、用途別、エンドユーザー別、地域別
  • 遠心式血液ポンプの世界市場（2023～2033）：種類別、エンドユーザー別
  • 眼科用ペリメーターの世界市場（2023～2033）：製品別、エンドユーザー別、地域別
  • 細胞・遺伝子療法製造の世界市場2023～2031：治療種類別、製品種類別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23AP140 )"T細胞療法の世界市場（2023～2033）：疾患別、治療種類別、モダリティ別、地域別" (英文：Global T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumours and Other Indications), by Therapy Type (CAR T-cell Therapy, TCR-based and TIL-based), by Modality (Research and Commercialized) and Region - 2023 to 2033)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。